Date: 2015-05-14
Type of information: Financing round
Company: Denali Therapeutics (USA - CA)
Investors: Fidelity Biosciences (USA - MA), ARCH Venture Partners (USA - IL), Flagship Ventures (USA - MA), Alaska Permanent Fund (USA - AK), sovereign wealth funds, public mutual funds and private family offices
Amount: $ 217 million
Funding type: financing round
Planned used: Denali Therapeutics is a new biotechnology company focused on developing effective therapies for neurodegenerative diseases. Denali is based on the collaboration of world-class scientists, industry experts and investors. Recent scientific insights into the genetic causes and biological processes underlying neurodegenerative disease, together with new translational medicine tools, offer an unprecedented opportunity to discover and develop effective medicines for Alzheimer\'s disease, Parkinson\'s disease, ALS and other neurodegenerative diseases. Denali\'s co-founders are Ryan Watts, Acting CEO, CSO and Board Member of Denali, former Director of the Department of Neuroscience at Genentech, Alexander Schuth, COO of Denali, former Director and Head of Neuroscience Partnering at Genentech, Marc Tessier-Lavigne, Chairman of the Board of Denali, President of The Rockefeller University. Denali\'s other founding board members are Robert Nelsen, Managing Director and Co-Founder of ARCH Venture Partners, Stacie Weninger, Executive Director of Fidelity Biosciences Research Initiative, Douglas Cole, Managing Partner of Flagship Ventures, Stephen Knight, Managing Partner of Fidelity Biosciences, Jay Flatley, CEO of Illumina, Vicki Sato, Professor of Management Practice at Harvard Business School, David Schenkein, CEO of Agios Pharmaceuticals. The founding investors include Fidelity Biosciences, ARCH Venture Partners, Flagship Ventures and the Alaska Permanent Fund (represented by Crestline Investors). Additional investors include sovereign wealth funds, public mutual funds and private family offices, with significant reserves for additional future financing.
Others: * On May 14, 2015, Denali Therapeutics, a new biotechnology company focused on developing effective therapies for neurodegenerative diseases, announced that it has launched with an initial investment commitment of $217 million. The founding investors include Fidelity Biosciences, ARCH Venture Partners, Flagship Ventures and the Alaska Permanent Fund (represented by Crestline Investors). Additional investors include sovereign wealth funds, public mutual funds and private family offices, with significant reserves for additional future financing.
Therapeutic area: Neurodegenerative diseases
